发布于: 雪球转发:5回复:49喜欢:1

VIR2218+VBI2601在APASL的英文Presentation

$腾盛博药-B(02137)$ $Vir Biotechnology(VIR)$ 

全部讨论

179和179+干扰素组各出现一例功能性治愈。179组32周就实现,179+干扰素组40周实现。

2023-02-19 13:49

T细胞应答不错,而且加179有可能不用再上干扰素。但179不加干扰素组AE也没有比+干扰素组具有明显优势…

2023-02-21 22:47

敢问老大vir看到多少?

2023-02-19 17:54

才50人?预计不是135人么

2023-02-18 23:22

看不懂,能说一下结论吗

2023-02-18 23:21

结合vir做的877+835的试验,我觉得路径很清晰了,前两个就是去实现大比例转阴,179去维持或者有可能提高这个后期的转阴率。

2023-02-18 22:55

pdf链接,网页链接

临床试验链接网页链接,主要终点有4个,分别是:Percentage of participants with sustained HBsAg loss during the 48-week follow-up period after NrtI withdrawal [ Time Frame: up to Week 96 ],
Number of participants with Adverse Events (AE) [ Time Frame: up to Week 96 ],
Number of participants with Serious Adverse Events (SAE) [ Time Frame: up to Week 96 ],
Number of participants with abnormalities in clinical laboratory tests [ Time Frame: up to Week 96 ]。

2023-02-18 22:39

在哪?vir的IR上没找到